Nature Communications (Jul 2022)
Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer
Abstract
Some cancer patients with impaired HLA-I still respond to immunotherapy. Here the authors combine a cytotoxic gene signature from CD4+ and CD8+ T cells with tumor mutational burden to predict immunotherapy response in NSCLC patients, including those with HLA-LOH.